Tema Heart & Health ETF (NASDAQ:HRTS) Stock Price Down 0.2% – Time to Sell?

Tema Heart & Health ETF (NASDAQ:HRTS)’s stock price dropped 0.2% during trading on Friday . The stock traded as low as $34.22 and last traded at $34.27. Approximately 5,567 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 6,390 shares. The stock had previously closed at $34.35.

Tema Heart & Health ETF Stock Performance

The company’s 50-day moving average price is $33.80 and its two-hundred day moving average price is $34.76. The stock has a market cap of $51.06 million, a PE ratio of 22.06 and a beta of 0.68.

Institutional Trading of Tema Heart & Health ETF

Several institutional investors and hedge funds have recently made changes to their positions in HRTS. Brookstone Capital Management purchased a new stake in shares of Tema Heart & Health ETF during the 4th quarter valued at $364,000. CoreCap Advisors LLC raised its position in shares of Tema Heart & Health ETF by 17.2% during the 4th quarter. CoreCap Advisors LLC now owns 60,679 shares of the company’s stock valued at $2,141,000 after buying an additional 8,903 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Tema Heart & Health ETF during the 3rd quarter valued at $243,000. Stifel Financial Corp raised its position in shares of Tema Heart & Health ETF by 19.8% during the 4th quarter. Stifel Financial Corp now owns 33,647 shares of the company’s stock valued at $1,187,000 after buying an additional 5,571 shares in the last quarter. Finally, Jane Street Group LLC raised its position in shares of Tema Heart & Health ETF by 9.4% during the 2nd quarter. Jane Street Group LLC now owns 37,164 shares of the company’s stock valued at $1,062,000 after buying an additional 3,202 shares in the last quarter.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.